[go: up one dir, main page]

WO2007069689A1 - Test d'aspiration utilisant un polysaccharide - Google Patents

Test d'aspiration utilisant un polysaccharide Download PDF

Info

Publication number
WO2007069689A1
WO2007069689A1 PCT/JP2006/324948 JP2006324948W WO2007069689A1 WO 2007069689 A1 WO2007069689 A1 WO 2007069689A1 JP 2006324948 W JP2006324948 W JP 2006324948W WO 2007069689 A1 WO2007069689 A1 WO 2007069689A1
Authority
WO
WIPO (PCT)
Prior art keywords
aspiration
polysaccharide
glucan
test
blood
Prior art date
Application number
PCT/JP2006/324948
Other languages
English (en)
Japanese (ja)
Inventor
Yasuhito Higashiyama
Shigeru Kohno
Yoshitsugu Miyazaki
Original Assignee
Nagasaki University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nagasaki University filed Critical Nagasaki University
Publication of WO2007069689A1 publication Critical patent/WO2007069689A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung

Definitions

  • the present invention relates to an aspiration test performed using a polysaccharide. More specifically, the present invention relates to an aspiration test drug containing a polysaccharide and an aspiration test method using the aspiration test drug.
  • the back of the throat is divided into a trachea that leads to the lungs and an esophagus that leads to the stomach.
  • a signal is transmitted to the brain, and the command from the brain closes the entrance of the trachea, and the food enters the esophagus.
  • these signals and instructions are not transmitted well, and food and saliva enter the trachea. This is called “aspiration”.
  • aspiration bacteria in food and saliva can also cause pneumonia because tracheal force also enters the lungs.
  • the pneumonia that develops in this way is aspiration pneumonia.
  • Non-Patent Document 1 An epidemiological survey of aspiration pneumonia in Japan is not clear, according to a survey in the United States, 5 to 15% of community-acquired pneumonia is pneumonia caused by aspiration (see Non-Patent Document 1). Its clinical features include episodes of aspiration in the history and clinical symptoms (inner meals, increased postprandial volume, the appearance of postprandial wheezing, the presence of occult aspiration), and the basis for aspiration There are foundational diseases and repeated aspiration.
  • a diagnosis of aspiration is considered indispensable for strategic intervention in the prevention and treatment of pneumonia in the elderly.
  • Known methods of testing for aspiration include the swallowing test, swallowing test, videofluorography, and RI.
  • the water drinking test (see Non-Patent Document 2) is the simplest method.
  • the subject is inspected for aspiration by observing the time until swallowing 10 to 30 ml of water and ending drinking, the presence or absence of swallowing, and how to drink.
  • the swallowing provocation test a small amount of distilled water is also injected into the tube placed in the oropharynx, and the time until swallowing is measured is measured. Then, if there is a disorder in the swallowing function, a diagnosis of aspiration is performed based on the fact that it takes a long time to be induced (see Non-Patent Document 2).
  • Videofluorography One is a method of recording a video by swallowing a diluted water-soluble contrast medium while seeing through it. If there is aspiration, the inflow to the trachea is confirmed, and this is used to diagnose aspiration.
  • An object of the present invention is to provide an aspiration test means that satisfies sensitivity, versatility, and practicality.
  • the present inventors found that the blood concentration of 1, 3 ⁇ -D glucan in a patient who aspirated an oral nutrient containing 1, 3- ⁇ -D-glucan was much higher than the normal value. (See Fig. 1). As a result of intensive studies to solve the above problems based on these findings, when 1,3- ⁇ -D glucan is ingested via the esophagus, 1,3- ⁇ -D glucan in the blood is ingested. The concentration did not increase, but when 1,3- ⁇ -D glucan was also ingested via the lungs, tracheal force was found to increase the blood 1,3- ⁇ -D glucan concentration. The invention has been completed.
  • the present invention is as follows.
  • An aspiration test kit comprising the aspiration test drug according to any one of [1] to [5] above and a polysaccharide measurement reagent.
  • a method for examining aspiration comprising the step of measuring the concentration of the polysaccharide in blood derived from a test subject who has taken the polysaccharide orally.
  • the aspiration test drug of the present invention it becomes possible to easily and accurately test for aspiration, leading to early detection of aspiration pneumonia that occurs frequently particularly in elderly people, and the disease Can contribute to prevention and treatment.
  • the aspiration test kit of the present invention since materials necessary for aspiration diagnosis are made into a kit, aspiration diagnosis can be performed more easily.
  • the present invention is expected to be highly applicable particularly as a test agent for examining the occurrence of aspiration during sleep.
  • Fig. 1 is a graph showing changes in the concentration of 1,3-—8-D-glucan in the blood of aspiration patients.
  • Aspiration means that food, beverages, saliva, etc. contained in the mouth are not sent to the stomach via the esophagus but are accidentally sent to the lungs via the trachea.
  • the aspiration test drug examines the occurrence of such aspiration.
  • the fact that food, beverages, saliva, etc. contained in the mouth are sent to the stomach via the esophagus is referred to as "absorption (or administration) of the transesophageal route” or “transesophageal absorption ( Or administration).
  • food, beverages and saliva contained in the mouth are sent to the lungs through the trachea and are called “transpulmonary route absorption (or administration)” or “transpulmonary absorption (or administration)” .
  • the expression “food was absorbed by the transpulmonary route” means that aspiration has occurred, and the expression “food has been absorbed by the transesophageal route” does not cause aspiration. It means that the food was successfully sent to the stomach.
  • “absorption” means transfer to blood.
  • the aspiration test drug of the present invention contains a polysaccharide.
  • This polysaccharide is a polymer compound in which monosaccharides (including substituted derivatives of monosaccharides) are polyglycosylated, and can be used without particular limitation as long as it is generally classified into polysaccharides.
  • Specific examples of polysaccharides include gnolecan, galactan, mannan, darcomannan, galatatomannan, mucopolysaccharide ( And chitin, hyaluronic acid, chondroitin, calcium spyran, fucoidan, etc.).
  • the polysaccharide contained in the aspiration test drug is not metabolized and decomposed into a monosaccharide (or disaccharide) when absorbed into the body, but at least 3 to 6 hours after absorption.
  • Those present in blood in the form of polysaccharides are preferred.
  • the polysaccharide is one that has no or little absorption by the transesophageal route.
  • dulcan examples include a-D glucan and 13-D glucan.
  • glucan includes derivatives thereof and salts thereof.
  • examples of the above-mentioned dulcan derivatives include those in which at least one of the alcoholic hydroxyl groups of the dalkane is derivatized.
  • Examples of the derivatization include etherification, esterification, cross-linking, and grafting.
  • ex D-glucan examples include starch, starch components (that is, amylose, amylopectin, dextran), pullulan, and nigeran.
  • j8-D glucan examples include 1, 3- ⁇ -D-glucan, 1,4- ⁇ -D glucan (eg, cellulose), 1,6- ⁇ -D-glucan (eg, contained in baker's yeast) Glucan).
  • ⁇ -D glucan derivatives include CM (carboxymethyl) cellulose. Cellulose is normally insoluble. CM cellulose in which the alcoholic hydroxyl group is substituted with a carboxymethyl group is water-soluble.
  • 1,3- ⁇ -D glucan as the polysaccharide contained in the aspiration test drug of the present invention.
  • the concentration of 1,3- ⁇ -D-glucan in the blood of the subject when aspiration occurs and when it does not occur Therefore, it is possible to accurately determine the occurrence of aspiration, and commercially available kits (for example, Fungitec (registered trademark) G test (manufactured by Seikagaku Corporation), ⁇ -glucantes Blood concentration of 1,3- ⁇ D glucan can be easily measured using Tokoichi (manufactured by Wako Pure Chemical Industries).
  • the 1,3- ⁇ D glucan includes, for example, zymosan, curdlan, pachyman, secretane tongue, lentinan, schizophyllan, coriolan, laminaran, lichenan, and derivatives thereof. Absent.
  • 1,3- ⁇ -D glucan is contained in, for example, mushrooms and fungal cell walls. Therefore, 1,3-—8-D glucan can be obtained by extraction using a conventionally known method of cell wall strength of mushrooms or fungi.
  • 1,3- ⁇ -D-Dalcan is included in oral nutrients (eg, Enshu Alquid (registered trademark)), CM-curdlan, lentinan, sonifiran, schizophyllan and the like. Therefore, these commercially available 1,3- ⁇ -D glucan preparations can be used as they are.
  • polysaccharides other than the above include j8-galactoglucin, peptide glucan, and xyloglucan, which are fungal cell wall components.
  • Aspiration is divided into two types: aspiration that occurs when awakening such as when eating, and aspiration that occurs when sleeping.
  • the dosage form of the aspiration test for diagnosing inapparent aspiration during sleep is preferably a gel.
  • the aspiration test drug of the present invention is a gel
  • the aspiration test drug can be made sticky and does not dissolve immediately when it is put in the mouth, but is maintained in the oral cavity for a certain period of time. It becomes possible to do. As a result, it can be effectively used for diagnosis of inapparent aspiration occurring during sleep.
  • the aspiration test glaze of the present invention may further contain a gelling agent, a thickener and the like in addition to the above-described polysaccharide.
  • the polysaccharide contained in the aspiration test drug is curdlan or the like, the polysaccharide itself can be gelled.
  • the gelling agent is generally used as a gelling agent for foods and pharmaceuticals. If it is, it can be used without being particularly limited. Specific examples of the gelling agent include agar, gelatin, egg white, and dielan gel. Among these, it is preferable to use gelatin in terms of particularly good adhesiveness.
  • the thickener can be used without particular limitation as long as it is generally used as a thickener for foods and pharmaceuticals.
  • the thickening agent include soft paraffin, aluminum stearate, cetostearyl alcohol, propylene glycol, polyethylene glycol, lanolin, hydrogenated lanolin, beeswax and the like.
  • gums such as xanthan gum, locust bean gum and gua gum can also be used as thickeners.
  • the aspiration test agent of the present invention may be used by mixing a plurality of the above-mentioned various gelling agents and thickening agents. Thereby, the adhesiveness of the aspiration test drug can be further increased.
  • the aspiration test drug of the present invention is preferably in a dosage form that can be adhered to the oral cavity and gradually dissolved after being adhered to the oral cavity. According to this, it becomes possible to affix the aspiration test medicine into the oral cavity and gradually dissolve it in the oral cavity, so that aspiration occurring during sleep can be diagnosed.
  • the aspiration test drug is one that dissolves gradually in about 1 to 10 hours, more preferably about 3 to 6 hours, after adhering to the oral cavity.
  • the dosage form of the aspiration test drug of the present invention is made into a soft candy-like gel by containing the gelling agent and Z or thickener as described above, the oral cavity of the subject before bedtime. (Specifically, the aspiration test drug is affixed to the back of the teeth, etc.) and the blood sugar concentration in the subject's blood is measured after waking up. Can be diagnosed. If such subclinical aspiration can be accurately diagnosed, it will be linked to the prevention or delay of onset of pneumonia in the elderly, and the medical benefits will be great.
  • the dosage form of the aspiration test drug of the present invention may be a solid without being limited to the gel as described above. In the case of a solid, it is preferable to form a film such as an wafer. According to this, as in the case of the gel, since the aspiration test drug can be stuck in the oral cavity of the subject, it can be used for diagnosis of occult aspiration.
  • the dosage form of the aspiration test drug of the present invention may be a film-coated tablet that can be stuck in the oral cavity.
  • This film-coated tablet is It can be prepared using additives such as oral pill cellulose, povidone, macrogol, D-sorbitol, and sucrose fatty acid ester.
  • This dosage form can also apply an aspiration test to the subject's mouth and is useful for the diagnosis of occult aspiration.
  • the dosage form of the aspiration test drug of the present invention may be an intraoral mucosal adhesive.
  • This intraoral mucosal adhesive can be prepared using additives such as hydroxypropylcellulose, carboxyvinyl polymer, magnesium stearate, lactose, talc, magnesium aluminate metasilicate.
  • This dosage form is also useful for diagnosing subclinical aspiration, as it allows aspiration testing drugs to be placed in the subject's mouth.
  • the aspiration test drug of the present invention may be contained in a mouthpiece or the like so that the aspiration test drug is gradually released into the oral cavity of the subject.
  • the amount of polysaccharide contained in the aspiration test agent of the present invention can achieve the object of the present invention (that is, the amount by which the blood concentration increases when absorbed by the transpulmonary route). However, it is, for example, 1 to: LOOOmg, preferably 1 to: LOOmg, more preferably 5 to 50 mg.
  • the ratio of the polysaccharide contained in the aspiration test drug of the present invention is not particularly limited as long as the object of the present invention can be achieved, but is, for example, 0.0001-99.9% by weight, preferably 10%. To 99.9% by weight, more preferably 30 to 99.9% by weight.
  • the aspiration test drug is first orally administered to the subject, blood is collected from the subject after a lapse of a certain time, and the polysaccharide in the blood is collected. You can measure the concentration of. If the aspiration test drug is liquid, the test drug can be taken as it is. If the aspiration test drug is a gel, the test drug can be applied to the oral cavity of the test subject.
  • the presence or absence of aspiration can be determined in humans or mammals other than humans. Therefore, the subject is not particularly limited as long as it is a mammal, but when it is intended to be useful for the treatment * prevention of aspiration pneumonia, the subject is preferably a human. In addition, since aspiration pneumonia occurs frequently particularly in elderly people, it is more preferable that the subjects are elderly people.
  • the aspiration test kit of the present invention includes the aspiration test drug of the present invention and a polysaccharide measurement reagent.
  • the polysaccharide measurement reagent contained in the aspiration test kit is a reagent for measuring the blood concentration of the polysaccharide contained in the aspiration test medicine that is kitted together. Appropriate reagents can be selected.
  • the aspiration test kit of the present invention a sample in which the aspiration test drug contains ⁇ D-glucan and the polysaccharide measurement reagent is i8-D glucan measurement reagent can be mentioned.
  • an aspiration test containing schizophyllan which is a kind of 1,3- ⁇ -D glucan preparation A combination of a drug and Fungitec (registered trademark) G test (manufactured by Seikagaku Corporation) as a ⁇ -D-glucan measurement reagent can be mentioned.
  • the test method for aspiration according to the present invention includes a step of measuring the concentration of the polysaccharide in blood derived from the test subject who has taken the polysaccharide orally.
  • the aspiration test method of the present invention uses the aspiration test drug of the present invention described above.
  • the test subject ingests the polysaccharide orally before performing the step of measuring the polysaccharide concentration.
  • the oral intake of the polysaccharide is carried out by orally administering an aspiration test drug to the test subject.
  • the presence or absence of aspiration can be determined in humans or non-human mammals. Therefore, the test subject is not particularly limited as long as it is a mammal, but when it is intended to be useful for the treatment * prevention of aspiration pneumonia, the subject is preferably a human.
  • aspiration pneumonia occurs frequently particularly in elderly people, it is more preferable that the subjects are elderly people.
  • a step of measuring the concentration of the polysaccharide in the blood derived from the test subject is performed. This measurement process is based on the fact that the blood translocation of polysaccharides is higher when taken pulmonary than when taken esophagus.
  • Target power Blood is collected and the concentration of the polysaccharide in the blood is measured to determine whether or not the polysaccharide contained in the aspiration test drug has migrated into the blood to be tested. Then, it is determined that aspiration has occurred when the blood concentration of the polysaccharide contained in the aspiration test drug is significantly higher than the blood concentration when the polysaccharide is ingested transesophageally.
  • the polysaccharide contained in the aspiration test drug is one that hardly or hardly moves into the blood when taken esophagus.
  • examples of such aspiration test agents include those containing 1, 3 ⁇ D glucan.
  • the method for measuring the concentration of polysaccharide in blood varies depending on the type of polysaccharide contained in the aspiration test drug, but various conventionally known methods can be employed.
  • the polysaccharide is 1,3- ⁇ -D-glucan, for example, Fungitec (registered trademark) G test (manufactured by Seikagaku Corporation), ⁇ -glucan test KOKO (manufactured by Wako Pure Chemical Industries), etc.
  • a concentration measurement kit In addition to using the above-mentioned commercially available kit, for example, it may be carried out using the method described in the patent document [Japanese Patent Laid-Open No. 7-184690 (publication date: July 25, 1995)]. it can.
  • the concentration can be measured using, for example, ELISA.
  • the presence or absence of aspiration is determined by the preferred method described above, it is preferable to measure the polysaccharide concentration in the blood to be examined before the step of administering the aspiration test drug. According to this, by comparing the numerical value before the administration process (this is the reference value) with the numerical value obtained in the measurement process (this is the measured value), it is possible to determine whether or not aspiration has occurred. Judgment can be made. In other words, when aspiration test is administered transesophageally without aspiration, the concentration of polysaccharide in the blood does not increase, so if the measured value is significantly higher than the reference value, It can be determined that aspiration has occurred.
  • the occurrence of aspiration can be more accurately diagnosed by comparing the reference value and the measured value of the same subject.
  • aspiration occurred because the concentration of 1,3- ⁇ -D glucan in the blood was higher than that in normal subjects even if aspiration did not occur. You can be misdiagnosed.
  • an aspiration test is performed using a method that compares the reference value and the measured value as described above, even if a patient with deep mycosis becomes a subject, the aspiration can be accurately detected. The presence or absence of occurrence can be determined.
  • use an aspiration test that contains polysaccharides other than 1,3- ⁇ -D glucan for example, CM cellulose.
  • a patient with graft-versus-host disease may have a blood galatato due to the destruction of the intestinal mucosal barrier caused by the disease even if aspiration has not occurred. Since the concentration of mannan is higher than that of normal subjects (Reference: Murashige N. et al., Clinic al Infectious Disease, 2004 Jan 15; 40: 333-4), misdiagnosis is occurring when aspiration occurs. It can be done. Even in this case, if the test for aspiration is performed using a method that compares the reference value with the measured value as described above, even if the subject is a patient with graft-versus-host disease (GVHD), Whether or not aspiration has occurred can be determined.
  • GVHD graft-versus-host disease
  • 1,3- ⁇ D —It can also be determined that aspiration has occurred when the concentration of glucan is measured to be 50 pgZml or more, preferably lOOpgZml or more.
  • This aspiration test method can be used for diagnosis of both aspiration during awakening and aspiration during sleep.
  • the aspiration test liquid is a liquid. After the administration process, several hours (about 3 to 6 hours) have passed. Blood can be collected and the concentration of polysaccharide in the serum can be measured.
  • the aspiration test drug is preferably an oblate shape or a soft candy shape. It can be placed in the oral cavity during sleep, and the blood of the subject can be collected the next morning and the polysaccharide concentration in the serum can be measured.
  • This method is used for diagnosis of conventional aspiration and is simpler and does not require any special equipment as compared with a conventional test (eg, videofluoridation, RI method).
  • clinicians including general practitioners can diagnose aspiration, and in particular, have the advantage of being able to accurately diagnose occult aspiration that is difficult to diagnose.
  • the blood concentration of 1, 3-13-D glucan in an aspiration patient receiving an oral nutritional product (trade name: Ensaliquid (registered trademark), manufactured by Dainippon Pharmaceutical Co., Ltd.) Measurement was performed using a Ku (registered trademark) G test (manufactured by Seikagaku Corporation).
  • Figure 1 shows the results. As shown in this figure, after the occurrence of aspiration (October 15th), the blood concentration of 1,3—
  • the 1,3- ⁇ -D glucan of the aspirated oral nutrient (Enshualiquid (registered trademark)) itself was measured to be 28,600 pg / ml. Very high value. This suggests that the increase in blood 1,3- ⁇ -D glucan concentration in aspiration patients is due to aspiration of an oral nutritional agent (Yenshuarikid (registered trademark)), which is mainly composed of soybeans. it was thought.
  • 1,3- ⁇ -D-glucan concentration in blood was measured when 1,3- ⁇ -D-glucan was administered to mice transpulmonary and transesophageally. The results of both were compared.
  • CM cardan (Curdlan) (manufactured by Wako Pure Chemical Industries, Ltd.) was used as 1,3- ⁇ -D glucan.
  • the obtained blood was immediately placed in a glucan-free centrifuge tube, centrifuged (3000 rpm, 5 minutes), and stored at 20 ° C until measurement. 1,3- ⁇ -D glucan was measured using Fungitec (registered trademark) G test manufactured by Seikagaku Corporation.
  • Examples 1 and 2 suggest that 1, 3- ⁇ -D-glucan may be one of the most important factors in determining aspiration. 1, 3
  • an aspiration test can be performed easily and accurately, leading to early detection of aspiration pneumonia that occurs frequently particularly in elderly people, and the disease. Can contribute to prevention and treatment.
  • the present invention is expected to be highly applicable as a test agent for examining the occurrence of aspiration particularly during sleep.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L’invention concerne un agent de test d'aspiration qui comprend un polysaccharide grâce auquel la présence ou l’absence d'aspiration peut être sûrement et commodément testée. Un test d'aspiration est réalisé en utilisant un agent de test d'aspiration qui contient un polysaccharide tel que le ß-D-glucan, en administrant l'agent de test d'aspiration par voie orale à un sujet et en mesurant ensuite la concentration en polysaccharide dans le sang du sujet. Bien que peu de polysaccharide migre dans le sang lorsque pris par voie œsophagienne, il émigre dans le sang lorsqu'il est administré par le poumon. L'aspiration est ainsi testée en mesurant la concentration du polysaccharide dans le sang du sujet et en déterminant si le polysaccharide contenu dans l'agent du test d'aspiration a migré ou non dans le sang du sujet.
PCT/JP2006/324948 2005-12-15 2006-12-14 Test d'aspiration utilisant un polysaccharide WO2007069689A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005362085 2005-12-15
JP2005-362085 2005-12-15

Publications (1)

Publication Number Publication Date
WO2007069689A1 true WO2007069689A1 (fr) 2007-06-21

Family

ID=38162991

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/324948 WO2007069689A1 (fr) 2005-12-15 2006-12-14 Test d'aspiration utilisant un polysaccharide

Country Status (1)

Country Link
WO (1) WO2007069689A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017522308A (ja) * 2014-07-21 2017-08-10 ネステク ソシエテ アノニム 安全な嚥下を促進する嚥下障害者用栄養製品

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0665106A (ja) * 1992-08-12 1994-03-08 Showa Yakuhin Kako Kk 嚥下機能診断用組成物
JPH11292796A (ja) * 1998-04-13 1999-10-26 Ina Food Ind Co Ltd 咀嚼・嚥下度合診断剤
JP2001048810A (ja) * 1999-08-04 2001-02-20 Ina Food Ind Co Ltd 造影剤用増粘剤
WO2004069179A2 (fr) * 2003-01-31 2004-08-19 Simply Thick Llc Boissons epaissies ameliorees pour la gestion de la dysphagie

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0665106A (ja) * 1992-08-12 1994-03-08 Showa Yakuhin Kako Kk 嚥下機能診断用組成物
JPH11292796A (ja) * 1998-04-13 1999-10-26 Ina Food Ind Co Ltd 咀嚼・嚥下度合診断剤
JP2001048810A (ja) * 1999-08-04 2001-02-20 Ina Food Ind Co Ltd 造影剤用増粘剤
WO2004069179A2 (fr) * 2003-01-31 2004-08-19 Simply Thick Llc Boissons epaissies ameliorees pour la gestion de la dysphagie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAKI T.: "Scintigraphy ni yoru E'nge Shogai no Hyoka", SHINKEI NAIKA, vol. 53, 25 September 2000 (2000-09-25), pages 194 - 195, XP003013982 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017522308A (ja) * 2014-07-21 2017-08-10 ネステク ソシエテ アノニム 安全な嚥下を促進する嚥下障害者用栄養製品

Similar Documents

Publication Publication Date Title
Heyland et al. Effect of postpyloric feeding on gastroesophageal regurgitation and pulmonary microaspiration: results of a randomized controlled trial
Riordan et al. Small intestinal bacterial overgrowth and the irritable bowel syndrome
Kingston et al. Increased incidence of nosocomial pneumonia in mechanically ventilated patients with subclinical aspiration
Baima et al. Periodontitis prevalence and severity in inflammatory bowel disease: A case–control study
Özdamar et al. Acute mesenteric lymphadenitis in children: findings related to differential diagnosis and hospitalization
Bar‐Meir capsule endoscopy–are all small intestinal lesions Crohn's disease?
Cengel et al. The role of ultrasonography in the imaging of body packers comparison with CT: a prospective study
Wesstrom et al. Congenital myotonic dystrophy: Incidence, clinical aspects and early prognosis
LIPSKI et al. Bacterial contamination of the small bowel in elderly people: is it necessarily pathological?
Schiff et al. Covid-19 presenting as a bulging fontanelle
Sinha et al. Infections and infestations of the gastrointestinal tract. Part 2: parasitic and other infections
WO2007069689A1 (fr) Test d'aspiration utilisant un polysaccharide
Sanhueza Palma et al. Typhoid fever: case report and literature review
EP0643830B1 (fr) Procede detection d'une alteration de l'epithelium gastrique
Erbaycu et al. What happens when oral tuberculosis is not treated?
Ramanathan et al. A study on the role of small intestinal bacterial overgrowth in patients with functional dyspepsia
Hall Canine diarrhoea: a rational approach to diagnostic and therapeutic dilemmas
RU2472445C1 (ru) Способ неинвазивной диагностики рака желудка
RU2794207C1 (ru) Способ уменьшения клинических проявлений атопического дерматита у детей, находящихся на грудном вскармливании
Sulthoni et al. Mortality risk factors in pneumonic children with congenital heart disease left to right shunt: A case-control study
Harirohman et al. Diagnostic problem on patient with tuberculous colitis mimicking Crohn’s disease
Rissi Giant Colonic Diverticulum-Rare Condition: Case Report
Ballah et al. International Journal of Medical Science and Clinical Research Studies
Stepanov et al. Prevalence of small intestinal bacterial overgrowth syndrome among patients with inflammatory bowel disease and its impact on nutritional status and clinical manifestations
Thiono et al. Mebendazole treatment in ascariasis re-infection of two-year-old boy in rural Ambon: a case report and literature review

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06834702

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP